Other Therapy Areas

Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.

Learn More →

    Home > Events > Triangle perspective on ai ml the future of drug development

    1 min read

    Triangle Perspective on AI, ML, & the Future of Drug Development

    Veristat Announces Participation in the "Triangle Perspective on AI, ML, & the Future of Drug Development" Panel Discussion 

    Veristat is excited to announce that our Chief Commercial Officer, Rachel Page, will be a panelist in the upcoming event organized by Sterling Bay, "Triangle Perspective on AI, ML, & the Future of Drug Development." This engaging panel discussion will feature five leading life sciences executives and two highly accomplished moderators examining the transformative impact of artificial intelligence (AI) and machine learning (ML) on the future of drug development.  

    Event Details: 

    Date and Time: Wednesday, July 17, 2024, 9:00 AM to 9:50 AM ET USA 

    Format: Webinar via Zoom (Zoom link will be distributed prior to the webinar. The session will be recorded and made available for those unable to attend live.) 

    Registration: Register Here

    Panel Discussion Highlights:

    The panel will focus on how AI/ML developments are revolutionizing the global biopharmaceutical industry, with a particular emphasis on the life sciences sector in North Carolina and the Research Triangle. Topics covered will include drug discovery, development, and deployment. 

    Panelists:

    Rachel Page, Chief Commercial Officer, Veristat  
    Joe Webb, Chief Executive Officer & Founder, Vitality Robotics 
    Julie Blasingim, Chief Executive Officer, Univo IRB 
    Mark Sydnor, President, Network Partners Group 
    Robin Hyde-DeRuyscher, President and Chief Scientific Officer, Emergo Therapeutics 

    Co-Moderators: 

    Kate Pestrichelli, Vice President, Program Management, Network Partners Group Stephanie Gaulding, Managing Director, Pharmatech Associates, a USP company 

    MC: 

    Michael Daniel, MSChE, Product Development Consultant, Pharma & CG Industries 

    Join Us: 

     Don't miss this opportunity to gain insights from industry leaders about the future of drug development in the age of AI and ML. We encourage you to register and invite others to attend this informative session. 

     We look forward to seeing you there and sharing how Veristat is contributing to advancements in the life sciences industry. 

    Registration: Register Here

     


     

     

     

     

     

     

     

     

    Share This Event:

       

    11 min read

    Monthly FDA Guidance and Regulatory News Review - September 2026

    This September 2026 regulatory update focuses on FDA’s new guidance on neonatal parenteral nutrition compounding and...

    8 min read

    Monthly FDA Guidance and Regulatory News Review - August 2026

    This August 2026 regulatory update focuses on the FDA finalizing three guidances addressing formal sponsor meetings,...